



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 8, 2020

Sujal Shah
Chief Executive Officer
CymaBay Therapeutics, Inc.
7575 Gateway Blvd, Suite 110
Newark, CA 94560

Re: CymaBay Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 2, 2020
File No. 333-239670

Dear Mr. Shah:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ada D. Sarmento at 202-551-3798 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Matthew B. Hemington, Esq.